Viking Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update

Go back to Viking Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 32.37 +1.99 (6.55%)
Previous Close $30.38    52 Week High $5.17 
Open $30.52    52 Week Low $0.94 
Day High $32.90    P/E N/A 
Day Low $30.52    EPS $0.00 
Volume 3,323,471